Related references
Note: Only part of the references are listed.Aglycosylated IgG variants expressed in bacteria that selectively bind FcγRI potentiate tumor cell killing by monocyte-dendritic cells
Sang Taek Jung et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site
Jenny Bostrom et al.
SCIENCE (2009)
Accentuate the negative, eliminate the positive: Engineering allergy therapeutics to block allergic reactivity through negative signaling
Andrew Saxon et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2008)
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
Ralf Bargou et al.
SCIENCE (2008)
Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin
Chengbin Wu et al.
NATURE BIOTECHNOLOGY (2007)
Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells
Ryutaro Asano et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library
We-Ching Liang et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
Recombinant approaches to IgG-like bispecific antibodies
JS Marvin et al.
ACTA PHARMACOLOGICA SINICA (2005)
A chimeric human-cat fusion protein blocks cat-induced allergy
DC Zhu et al.
NATURE MEDICINE (2005)
The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation
S Holgate et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2005)
Fc receptor targeting in the treatment of allergy, autoimmune diseases and cancer
A Nakamura et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2005)
Engineered antibody fragments and the rise of single domains
P Holliger et al.
NATURE BIOTECHNOLOGY (2005)
A revival of bispecific antibodies
P Kufer et al.
TRENDS IN BIOTECHNOLOGY (2004)
Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions
SS Sidhu et al.
JOURNAL OF MOLECULAR BIOLOGY (2004)
Omalizumab-induced reductions in mast cell FcεRI expression and function
LA Beck et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2004)
High-affinity human antibodies from phage-displayed synthetic fab libraries with a single framework scaffold
CV Lee et al.
JOURNAL OF MOLECULAR BIOLOGY (2004)
A bispecific antibody against human IgE and human FcγRII that inhibits antigen-induced histamine release by human mast cells and basophils
SW Tam et al.
ALLERGY (2004)
A novel human immunoglobulin Fcγ-Fcε bifunctional fusion protein inhibits FcεRI-mediated degranulation
DC Zhu et al.
NATURE MEDICINE (2002)
Expression of full-length immunoglobulins in Escherichia coli:: rapid and efficient production of aglycosylated antibodies
LC Simmons et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2002)
Bispecific and bifunctional single chain recombinant antibodies
J Kriangkum et al.
BIOMOLECULAR ENGINEERING (2001)
High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR
RL Shields et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Bispecific human IgG by design
P Carter
JOURNAL OF IMMUNOLOGICAL METHODS (2001)
Immunotherapeutic perspective for bispecific antibodies
AB van Spriel et al.
IMMUNOLOGY TODAY (2000)
Negative regulation of FcεRI signaling by FcγRII costimulation in human blood basophils
CL Kepley et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2000)
Share Paper
